Eyenovia
  • Home
  • About
    • About Eyenovia
    • Vision
    • Leadership
  • Technology
  • Pipeline
    • Eyenovia Pipeline
    • MydCombi (Mydriasis)
    • MicroLine (Presbyopia)
    • MicroPine (Myopia)
  • Partners
  • Investors
  • News + Resources
    • News
    • Resource Library
  • Menu Menu
Print Friendly, PDF & Email

High-precision piezo-ejection ocular microdosing Phase II study on local and systemic effects of topical phenylephrine

Recent Posts

  • Eyenovia Announces FDA Approval of Mydcombiâ„¢, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform May 8, 2023
  • Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update March 30, 2023
  • Eyenovia Announces Independent Director Stephen Benjamin To Step Down To Assume Role Of Head Of White House’s Office Of Public Engagement March 2, 2023

Pipeline and Technology

  • MydCombi (Mydriasis)
  • MicroLine (Presbyopia)
  • MicroPine (Myopia)
  • Technology

Corporate Address

Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenoviabio.com

Copyright © 2023 Eyenovia, Inc. All rights reserved.
  • Twitter
  • Facebook
  • LinkedIn
  • Contact
  • Safe Harbor
  • Privacy Policy
  • Terms of Use
Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Pres...Juvenile Myopia Progression, Risk Factors and Interventions
Scroll to top